News

Home > News > News

2018/03/01

CCSB obtained TW patent for crystal form D of Baricitinib phosphate.

The Taiwanese Patent Office has granted Chunghwa Chemical Synthesis & Biotech Co. Ltd. (CCSB) a polymorph patent on the API manufacturing of novel crystal form D of Baricitinib phosphate on March 1st, 2018. The patent “CRYSTAL FORM D OF BARICITINIB PHOSPHATE AND COMPOSITION” (I 616447) is based on proprietary technology developed by CCSB, including novel manufacturing method and solutions to obtain novel crystal form D of Baricitinib phosphate. The crystal form D of Baricitinib phosphate of the present invention is stable and can be used as an active pharmaceutical ingredient for pharmaceutical composition for the treatment of autoimmune diseases, especially rheumatoid arthritis.